Cargando…
Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster is one of the most essential strategies against coronavirus disease 2019 (COVID-19) in the era of emerging variants. However, the effectiveness of SARS-CoV-2 vaccine boosters has not much been investigated in hemodialys...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967999/ https://www.ncbi.nlm.nih.gov/pubmed/36851757 http://dx.doi.org/10.3390/v15020543 |
_version_ | 1784897405336944640 |
---|---|
author | Chen, Po-Chun Huang, Chiang-Chi Fu, Chung-Ming Chang, Yi-Chin Wu, Po-Jung Lee, Wen-Chin Lee, Chien-Te Tsai, Kai-Fan |
author_facet | Chen, Po-Chun Huang, Chiang-Chi Fu, Chung-Ming Chang, Yi-Chin Wu, Po-Jung Lee, Wen-Chin Lee, Chien-Te Tsai, Kai-Fan |
author_sort | Chen, Po-Chun |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster is one of the most essential strategies against coronavirus disease 2019 (COVID-19) in the era of emerging variants. However, the effectiveness of SARS-CoV-2 vaccine boosters has not much been investigated in hemodialysis (HD) patients receiving oral antiviral agents. In this retrospective study involving 258 HD patients with COVID-19 receiving molnupiravir, we stratified the study cohort according to vaccination status and compared the baseline characteristics and risks of 30-day composite events (COVID-19-related acute care visits, hospitalization, or mortality) among groups. Our analysis demonstrated that the SARS-CoV-2 vaccine boosters markedly decreased the risk of composite events in HD patients (hazard ratio (95% confidence interval), 0.163 (0.063–0.423) for three vs. ≤ two doses of vaccination, p < 0.001; 0.309 (0.115–0.830) for four vs. ≤ two doses of vaccination, p = 0.020). The benefits of vaccine boosters were similar between patients receiving mRNA-based and protein-based boosters and between those with post-booster intervals of ≤ 120 and > 120 days. In conclusion, for HD patients with initially mild or asymptomatic COVID-19 receiving molnupiravir, the benefits of SARS-CoV-2 vaccine boosters are prominent, irrespective of booster vaccine types. |
format | Online Article Text |
id | pubmed-9967999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99679992023-02-27 Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir Chen, Po-Chun Huang, Chiang-Chi Fu, Chung-Ming Chang, Yi-Chin Wu, Po-Jung Lee, Wen-Chin Lee, Chien-Te Tsai, Kai-Fan Viruses Article The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster is one of the most essential strategies against coronavirus disease 2019 (COVID-19) in the era of emerging variants. However, the effectiveness of SARS-CoV-2 vaccine boosters has not much been investigated in hemodialysis (HD) patients receiving oral antiviral agents. In this retrospective study involving 258 HD patients with COVID-19 receiving molnupiravir, we stratified the study cohort according to vaccination status and compared the baseline characteristics and risks of 30-day composite events (COVID-19-related acute care visits, hospitalization, or mortality) among groups. Our analysis demonstrated that the SARS-CoV-2 vaccine boosters markedly decreased the risk of composite events in HD patients (hazard ratio (95% confidence interval), 0.163 (0.063–0.423) for three vs. ≤ two doses of vaccination, p < 0.001; 0.309 (0.115–0.830) for four vs. ≤ two doses of vaccination, p = 0.020). The benefits of vaccine boosters were similar between patients receiving mRNA-based and protein-based boosters and between those with post-booster intervals of ≤ 120 and > 120 days. In conclusion, for HD patients with initially mild or asymptomatic COVID-19 receiving molnupiravir, the benefits of SARS-CoV-2 vaccine boosters are prominent, irrespective of booster vaccine types. MDPI 2023-02-16 /pmc/articles/PMC9967999/ /pubmed/36851757 http://dx.doi.org/10.3390/v15020543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Po-Chun Huang, Chiang-Chi Fu, Chung-Ming Chang, Yi-Chin Wu, Po-Jung Lee, Wen-Chin Lee, Chien-Te Tsai, Kai-Fan Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title | Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title_full | Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title_fullStr | Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title_full_unstemmed | Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title_short | Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir |
title_sort | real-world effectiveness of sars-cov-2 vaccine booster in hemodialysis patients with covid-19 receiving molnupiravir |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967999/ https://www.ncbi.nlm.nih.gov/pubmed/36851757 http://dx.doi.org/10.3390/v15020543 |
work_keys_str_mv | AT chenpochun realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT huangchiangchi realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT fuchungming realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT changyichin realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT wupojung realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT leewenchin realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT leechiente realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir AT tsaikaifan realworldeffectivenessofsarscov2vaccineboosterinhemodialysispatientswithcovid19receivingmolnupiravir |